avac

Global Health Watch: LEN Access Pathways, NIAID Reorganization, Global Fund Report, NIH Lawsuit

This week’s issue covers developments shaping access to HIV prevention and the future of US biomedical research, including new pathways to accelerate access to lenacapavir for HIV PrEP, calls for ...
avac

Artificial Intelligence in the HIV response: All the good stuff from AIDS2026

An analysis by Jirair Ratevosian of the Duke Global Health Institute looked comprehensively at AI-related abstracts, key themes from use cases, and emerging trends at AIDS 2026. His review shows the ...
avac

Global Health Watch: NIH-DoD Deal & NIAID Restructuring, Ebola Vaccine Progress, Gavi Funding Resumes, New US Foreign Aid Leadership

The US National Institutes of Health (NIH) signs a 10-year agreement that could move significant NIAID research funding to the Department of Defense, as NIAID separately proposes a major restructuring ...
avac

The Clinical Trial Design Academy: Equipping Advocates to Shape HIV Prevention Research Decisions and Move the Research Agenda Forward

HIV prevention research must be conducted in collaboration with the communities it intends to serve; decisions about study design, participant populations and locations, conduct, and future access ...
avac

The Impact Report

Scientific breakthroughs in HIV prevention depend on community engagement that drives successful research, development, acceptance and uptake of new products. In 2007, emerging from controversies that ...
avac

Harnessing Artificial Intelligence for HIV: Breakthrough or Buzzword?

This presentation by Izukanji Sikazwe, Head of HIV at The Global Fund, during AIDS 2026 explores how the field might harness artificial intelligence in response to HIV. Izukanji Sikazwe unpacks what ...
avac

EXPrESSIVE-11 Communications Toolkit

Downloadable materials to foster community interest, awareness and engagement in the EXPrESSIVE-11 trials, tailored to the local languages and reflecting the lived realities of communities in ...
avac

Alimatravir (AMI) for PrEP

Alimatravir (AMI) is an investigational monthly pill for HIV prevention developed by Merck/MSD. AMI is currently in phase 3 efficacy trials: EXPrESSIVE-10 and EXPrESSIVE-11. EXPrESSIVE-10 launched in ...
avac

Embedding Good Participatory Practice in PURPOSE 1

Gilead’s PURPOSE program is comprised of six clinical trials investigating the efficacy of long-acting injectable lenacapavir (LEN) for PrEP among diverse populations. PURPOSE 1, the first trial in ...
avac

Using a Transformative Human-Centered Design Approach to Co-Create Communication Materials for the Alimatravir Efficacy Trial, EXPrESSIVE-11

Merck’s EXPrESSIVE program is investigating the efficacy of alimatravir (AMI) for monthly oral PrEP. With support from the Gates Foundation, AVAC works to ensure there is strong, consistent engagement ...
avac

Global Health Watch: Steinem’s Legacy, US Global Health Aid Cuts; OMB Grant Rule Delayed; Future of Global Health Reform

We’ve lost another champion for global health and reproductive rights this week: Gloria Steinem, the pioneering feminist and activist who spent decades fighting for gender equality, reproductive ...